Elan's $375 mil. acquisition of Sano brings two Phase III transdermal projects.
Executive Summary
ELAN ACQUISITION OF SANO BRINGS TWO PHASE III TRANSDERMAL PROJECTS to Elan's development portfolio, the company said Dec. 15. Sano's highest profile project is a transdermal formulation of Bristol-Myers Squibb's anxiolytic BuSpar (buspirone), and the company also has a smoking cessation patch in Phase III.